These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21813713)

  • 1. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.
    Mayne J; Dewpura T; Raymond A; Bernier L; Cousins M; Ooi TC; Davignon J; Seidah NG; Mbikay M; Chrétien M
    Clin Chem; 2011 Oct; 57(10):1415-23. PubMed ID: 21813713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.
    Mayne J; Ooi TC; Raymond A; Cousins M; Bernier L; Dewpura T; Sirois F; Mbikay M; Davignon J; Chrétien M
    Lipids Health Dis; 2013 May; 12():70. PubMed ID: 23663650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.
    Cariou B; Ouguerram K; Zaïr Y; Guerois R; Langhi C; Kourimate S; Benoit I; Le May C; Gayet C; Belabbas K; Dufernez F; Chétiveaux M; Tarugi P; Krempf M; Benlian P; Costet P
    Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2191-7. PubMed ID: 19762784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation.
    Noguchi T; Katsuda S; Kawashiri MA; Tada H; Nohara A; Inazu A; Yamagishi M; Kobayashi J; Mabuchi H
    Atherosclerosis; 2010 May; 210(1):166-72. PubMed ID: 20006333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.
    Zhao Z; Tuakli-Wosornu Y; Lagace TA; Kinch L; Grishin NV; Horton JD; Cohen JC; Hobbs HH
    Am J Hum Genet; 2006 Sep; 79(3):514-23. PubMed ID: 16909389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma PCSK9 levels correlate with cholesterol in men but not in women.
    Mayne J; Raymond A; Chaplin A; Cousins M; Kaefer N; Gyamera-Acheampong C; Seidah NG; Mbikay M; Chrétien M; Ooi TC
    Biochem Biophys Res Commun; 2007 Sep; 361(2):451-6. PubMed ID: 17645871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
    Humphries SE; Neely RD; Whittall RA; Troutt JS; Konrad RJ; Scartezini M; Li KW; Cooper JA; Acharya J; Neil A
    Clin Chem; 2009 Dec; 55(12):2153-61. PubMed ID: 19797716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
    Alborn WE; Cao G; Careskey HE; Qian YW; Subramaniam DR; Davies J; Conner EM; Konrad RJ
    Clin Chem; 2007 Oct; 53(10):1814-9. PubMed ID: 17702855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ; Li JJ
    Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel splicing variant of proprotein convertase subtilisin/kexin type 9.
    Schmidt RJ; Zhang Y; Zhao Y; Qian YW; Wang H; Lin A; Ehsani ME; Yu X; Wang G; Singh J; Su EW; Li S; Konrad RJ; Cao G
    DNA Cell Biol; 2008 Apr; 27(4):183-9. PubMed ID: 18052825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.
    Lagace TA; Curtis DE; Garuti R; McNutt MC; Park SW; Prather HB; Anderson NN; Ho YK; Hammer RE; Horton JD
    J Clin Invest; 2006 Nov; 116(11):2995-3005. PubMed ID: 17080197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
    Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
    Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor.
    Garvie CW; Fraley CV; Elowe NH; Culyba EK; Lemke CT; Hubbard BK; Kaushik VK; Daniels DS
    Protein Sci; 2016 Nov; 25(11):2018-2027. PubMed ID: 27534510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
    Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
    PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
    Cameron J; Holla ØL; Ranheim T; Kulseth MA; Berge KE; Leren TP
    Hum Mol Genet; 2006 May; 15(9):1551-8. PubMed ID: 16571601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
    Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
    Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.